Cellectis (CLLS) FCF Margin (QoQ) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Cellectis | 20.83 Bn | 20.62 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -16,590.00 |
| Dec 31, 2025 | -9,516.00 |
| Sep 30, 2025 | 5,871.00 |
| Jun 30, 2025 | 9,752.00 |
| Mar 31, 2025 | -13,452.00 |
| Dec 31, 2024 | 836.00 |
| Sep 30, 2024 | -69,138.00 |
| Jun 30, 2024 | 117,028.00 |
| Mar 31, 2024 | -1.56 Mn |
| Dec 31, 2023 | 2.59 Mn |
| Sep 30, 2023 | -27,918.00 |
| Jun 30, 2023 | 967,855.00 |
| Sep 30, 2022 | -1.29 Mn |
| Jun 30, 2022 | -133,834.00 |
| Sep 30, 2021 | -25,082.00 |
| Jun 30, 2021 | -1,662.00 |
| Mar 31, 2021 | 73,490.00 |
| Dec 31, 2020 | -46,609.00 |
| Sep 30, 2020 | -2,760.00 |
| Jun 30, 2020 | -30,300.00 |
| Mar 31, 2020 | 70,834.00 |
| Dec 31, 2019 | -48,721.00 |
| Sep 30, 2019 | 137,881.00 |
| Jun 30, 2019 | 40,582.00 |
| Mar 31, 2019 | 87,822.00 |
| Dec 31, 2018 | -134,443.00 |
| Sep 30, 2018 | -128,333.00 |
| Jun 30, 2018 | 8,273.00 |
| Mar 31, 2018 | -12,109.00 |
| Dec 31, 2017 | 4,432.00 |
| Sep 30, 2017 | 890.00 |
| Jun 30, 2017 | -1,878.00 |
| Mar 31, 2017 | 6,637.00 |
| Dec 31, 2016 | -30,508.00 |
| Sep 30, 2016 | 119,404.00 |
| Jun 30, 2016 | -100,318.00 |
| Mar 31, 2016 | -26,386.00 |
| Dec 31, 2015 | 13,626.00 |
| Sep 30, 2015 | 15,706.00 |
| Jun 30, 2015 | -23,334.00 |